SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
Q2 2022 vs. Q1 2022
How the institutions holding SAB Biotherapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 27 | 37 | +10 |
| Shares | 1.79M | 3.08M | +1.29M (+72.3%) |
| Value | $6.71M | $4.45M | −$2.27M (−33.8%) |
New holders (13)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| First PREMIER Bank | 652,440 | $946.0K | 0.28% |
| Meteora Capital, LLC | 292,538 | $424.0K | 0.08% |
| Bridgeway Capital Management, LLC | 84,000 | $122.0K | 0.00% |
| Millennium Management LLC | 64,220 | $93.0K | 0.00% |
| Silver Oak Securities, Inc | 51,941 | $64.0K | 0.01% |
| LGL Partners, LLC | 23,000 | $33.0K | 0.01% |
| AE Wealth Management LLC | 18,700 | $27.0K | 0.00% |
| Charles Schwab Investment Management Inc | 16,238 | $24.0K | 0.00% |
| Brookstone Capital Management | 19,618 | $24.0K | 0.00% |
| Elgethun Capital Management | 13,296 | $18.0K | 0.01% |
| Kestra Advisory Services, LLC | 11,000 | $16.0K | 0.00% |
| 1st Source Bank | 10,000 | $15.0K | 0.00% |
| Wells Fargo & Company | 167 | $0 | 0.00% |
Sold out (3)
Institutions that held SAB Biotherapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Alps Advisors Inc | 45,083 | $170.0K |
| Qube Research & Technologies Ltd | 24,179 | $91.0K |
| Money Concepts Capital Corp | 250 | $1.00K |